Despite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models ...

Please provide your email address to receive an email when new articles are posted on . The combination of mezigdomide and dexamethasone exhibited activity among patients with heavily pretreated ...

Mezigdomide, which is the centerpiece of this trial, is a newer derivative of thalidomide. And for those uninformed, the thalidomide derivatives are probably the most important drugs that have been ...

The investigational oral therapy KTX-1001, also known as gintemetostat, is catching interest as a potential treatment for a subgroup of patients with multiple myeloma, as an expert explained in a ...

Mezigdomide plus Velcade and dexamethasone or Kyprolis and dexamethasone showed promising response rates across multiple doses in patients with relapsed or refractory multiple myeloma, research showed ...

All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...

NEWTON, Mass., Oct. 30, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has ...

PRINCETON, N.J., June 12, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new data from its targeted protein degradation platform during the 2025 European ...

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and ...